[Study of the effect of medicinal product "STRESSEN" on blood levels of homocysteine in patients with current cardiovascular disease].
The relationship between cardiovascular disease and high plasma levels of homocysteine is known; it is therefore necessary to keep the concentrations of this amino acid, considered an independent risk factor for these pathologies, within the physiological range. The objective of this study is to evaluate the efficacy of the medicinal product STRESSEN on homocysteinemia in patients with current cardiovascular disease. The study was carried out on 40 patients with homocysteinemia higher than 14 micromol/l. Patients were divided into 2 groups of 20: one was treated with STRESSEN for 30 days and the other did not receive any specific therapy. Homocysteinemia was evaluated at t = 0 and t = 30 days in both groups. STRESSEN determined a significative mean reduction of 39.2% (P < 0.0001) of plasma levels of the considered amino acid, which on the contrary did not change in non treated patients. The results of this study show the efficacy of STRESSEN in reducing homocysteinemia and, consequently, the risk of coronary disease.